Now P&G points the finger

February 10, 2006

Pharmaceutical giant Procter & Gamble has been praised for taking a rare stand for honesty in drug marketing by suing its rivals, Roche and GlaxoSmithKline, over allegedly misleading claims that they have made about the effectiveness of their osteoporosis drug Boniva. This is the same P&G, of course, that has been facing international criticism since The Times Higher reported that the company released research findings on its own osteoporosis drug, Actonel, in the name of academic researchers whose access to the drug's raw trial data had been seriously restricted.

Please login or register to read this article

Register to continue

Get a month's unlimited access to THE content online. Just register and complete your career summary.

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments